Business Description
BioVaxys Technology Corp
NAICS : 541710
SIC : 3741
ISIN : CA09076M1014
Share Class Description:
BVAXF: Ordinary SharesDescription
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.03 | |||||
Equity-to-Asset | -2.63 | |||||
Debt-to-Equity | -0.04 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40 | |||||
3-Year EPS without NRI Growth Rate | 40.7 | |||||
3-Year FCF Growth Rate | 38.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.8 | |||||
9-Day RSI | 54.34 | |||||
14-Day RSI | 53.38 | |||||
3-1 Month Momentum % | 253.75 | |||||
6-1 Month Momentum % | -6.14 | |||||
12-1 Month Momentum % | -35.19 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.28 | |||||
Quick Ratio | 0.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -41.7 | |||||
Shareholder Yield % | -89.62 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -403.97 | |||||
ROIC % | -1312.9 | |||||
3-Year ROIIC % | -41.6 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.6 | |||||
EV-to-EBITDA | -0.6 | |||||
EV-to-FCF | -0.98 | |||||
Earnings Yield (Greenblatt) % | -166.67 | |||||
FCF Yield % | -106.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:BVAXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioVaxys Technology Corp Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.116 | ||
| Beta | 5.8974 | ||
| 3-Year Sharpe Ratio | 0.39 | ||
| 3-Year Sortino Ratio | 1.22 | ||
| Volatility % | 242.08 | ||
| 14-Day RSI | 53.38 | ||
| 14-Day ATR ($) | 0.056793 | ||
| 20-Day SMA ($) | 0.141347 | ||
| 12-1 Month Momentum % | -35.19 | ||
| 52-Week Range ($) | 0.0209 - 0.29 | ||
| Shares Outstanding (Mil) | 40.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioVaxys Technology Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioVaxys Technology Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2025-09-11 | 0.22 (+11.45%) | ||
| 2:1 Stock Split | 2020-04-28 | 1.36 (+12.23%) |
Show
Entries
BioVaxys Technology Corp Frequently Asked Questions
What is BioVaxys Technology Corp(BVAXF)'s stock price today?
The current price of BVAXF is $0.15. The 52 week high of BVAXF is $0.29 and 52 week low is $0.02.
When is next earnings date of BioVaxys Technology Corp(BVAXF)?
The next earnings date of BioVaxys Technology Corp(BVAXF) is .
Does BioVaxys Technology Corp(BVAXF) pay dividends? If so, how much?
BioVaxys Technology Corp(BVAXF) does not pay dividend.
Guru Commentaries on OTCPK:BVAXF
No articles.
Press Release
Articles on BioVaxys Technology Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers